receptor affinity is a starting point in most successful drug development programs, but we know that selectivity, bioavailability, PK etc all contribute to the usefulness (or not) of a drug. Here is a snippet of usefull info:
Hilarious. The quote is the exact same quote I've pasted and linked to already today. Funnily enough, it hasn't changed and still supports everything I've been saying. Nice try.
And I agree, "receptor affinity is a starting point," and based on the receptor studies and other epidemiological and animal studies, iradipine was determined the best candidate to move forward and then successfully completed Phase 2 and Phase 3, unlike any other CCB for PD.